Calculate the HAS-BLED score for major bleeding risk in atrial fibrillation patients on anticoagulation. Guides risk factor modification, not anticoagulation decisions.
The HAS-BLED score assesses the one-year risk of major bleeding in patients with atrial fibrillation (AF) receiving anticoagulation therapy. Developed from the Euro Heart Survey on AF population, HAS-BLED evaluates nine modifiable and non-modifiable risk factors: Hypertension, Abnormal renal/liver function, Stroke, Bleeding history, Labile INR, Elderly, and Drugs/alcohol.
Critically, a high HAS-BLED score (≥3) does NOT contraindicate anticoagulation. Instead, it identifies patients who need closer monitoring and focused attention to modifiable bleeding risk factors — controlling blood pressure, switching from warfarin to DOAC if INR is labile, discontinuing unnecessary NSAIDs, and addressing alcohol use.
HAS-BLED should always be interpreted alongside the CHA₂DS₂-VASc stroke risk score. In most patients, the stroke risk of untreated AF significantly exceeds the bleeding risk of anticoagulation, making treatment beneficial even at HAS-BLED ≥3. Check the example with realistic values before reporting. Use the steps shown to verify rounding and units. Cross-check this output using a known reference case. Use the example pattern when troubleshooting unexpected results.
Bleeding risk assessment is essential for safe anticoagulation management. HAS-BLED serves two critical purposes: (1) identifying modifiable risk factors that can be addressed to lower bleeding risk, and (2) flagging patients who need more frequent monitoring. The 2020 ESC AF guidelines specifically recommend HAS-BLED as the preferred bleeding risk tool because it highlights actionable targets.
Unlike older tools that simply estimated bleeding probability, HAS-BLED empowers clinicians to actively reduce risk rather than simply avoiding anticoagulation.
HAS-BLED = H + A + S + B + L + E + D H = Hypertension (uncontrolled SBP >160): 1 point A = Abnormal renal AND/OR liver function: 1 each (max 2) S = Stroke history: 1 point B = Bleeding history or predisposition: 1 point L = Labile INR (TTR <60% on warfarin): 1 point E = Elderly (>65 years): 1 point D = Drugs (antiplatelets/NSAIDs) AND/OR alcohol excess: 1 each (max 2) Total: 0-9 points
Result: HAS-BLED 3 — High Bleeding Risk
A score of 3 (hypertension + labile INR + elderly) puts this patient at high bleeding risk (~5.8%/year). Modifiable factors: control blood pressure to <140/90 and switch from warfarin to a DOAC to eliminate the labile INR point. This would reduce the score to 1 (elderly only).
The most common actionable finding from HAS-BLED assessment is identifying patients on unnecessary concomitant antiplatelet therapy or NSAIDs. Dual antiplatelet + anticoagulant therapy dramatically increases bleeding risk and should be time-limited after coronary stenting. Similarly, NSAIDs should be replaced with non-bleeding-risk analgesics whenever possible.
Mathematically, the net clinical benefit of anticoagulation = (stroke rate without treatment × impact of stroke) − (major bleed rate with treatment × impact of bleed). Because ischemic strokes are generally more devastating than major bleeds (except intracranial hemorrhage), the net benefit favors anticoagulation in virtually all patients with CHA₂DS₂-VASc ≥2.
Genetics (CYP2C9, VKORC1) and biomarkers (GDF-15, hs-troponin) are being investigated to refine bleeding risk prediction beyond clinical scores. Machine learning models may improve discrimination, though HAS-BLED remains the standard due to simplicity, validation, and focus on modifiable targets.
No. A high HAS-BLED score identifies patients who need risk factor modification and closer monitoring, not anticoagulation discontinuation. In most AF patients, the stroke risk (assessed by CHA₂DS₂-VASc) far exceeds the bleeding risk. Guidelines specifically warn against withholding anticoagulation solely based on HAS-BLED.
DOACs (apixaban, rivarelbaan, edoxaban, dabigatran) have lower rates of intracranial hemorrhage compared to warfarin and do not require INR monitoring. Apixaban has the lowest bleeding rates among DOACs. For patients with labile INR on warfarin, switching to a DOAC both improves efficacy and reduces the HAS-BLED score.
HAS-BLED has been validated in multiple AF cohorts and outperforms HEMORR₂HAGES and ATRIA bleeding scores in terms of discrimination and clinical utility. The 2020 ESC guidelines recommend HAS-BLED as the preferred tool. Its key advantage is the focus on modifiable risk factors.
Major bleeding is defined by the ISTH criteria: fatal bleeding, symptomatic bleeding in a critical area/organ (intracranial, intraspinal, intraocular, retroperitoneal, pericardial, intramuscular with compartment syndrome), or bleeding with hemoglobin drop ≥2 g/dL or requiring ≥2 units of RBC transfusion. Use this as a practical reminder before finalizing the result.
HAS-BLED was originally derived in warfarin-treated patients, but it has been validated in DOAC populations as well. The "labile INR" criterion does not apply to DOAC patients and should be scored as 0, effectively lowering HAS-BLED in DOAC users by 1 point compared to poorly-controlled warfarin users.
Reassess at least annually and whenever clinical circumstances change (new medications, renal function decline, falls). Some modifiable risk factors (blood pressure control, medication changes) can reduce the score at subsequent visits.